206 related articles for article (PubMed ID: 11502522)
1. Specific inhibition of human immunodeficiency virus type 1 (HIV-1) integration in cell culture: putative inhibitors of HIV-1 integrase.
Vandegraaff N; Kumar R; Hocking H; Burke TR; Mills J; Rhodes D; Burrell CJ; Li P
Antimicrob Agents Chemother; 2001 Sep; 45(9):2510-6. PubMed ID: 11502522
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of human immunodeficiency virus type 1 integration by diketo derivatives.
Pluymers W; Pais G; Van Maele B; Pannecouque C; Fikkert V; Burke TR; De Clercq E; Witvrouw M; Neamati N; Debyser Z
Antimicrob Agents Chemother; 2002 Oct; 46(10):3292-7. PubMed ID: 12234864
[TBL] [Abstract][Full Text] [Related]
3. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells.
Hazuda DJ; Felock P; Witmer M; Wolfe A; Stillmock K; Grobler JA; Espeseth A; Gabryelski L; Schleif W; Blau C; Miller MD
Science; 2000 Jan; 287(5453):646-50. PubMed ID: 10649997
[TBL] [Abstract][Full Text] [Related]
4. Mode of interaction of G-quartets with the integrase of human immunodeficiency virus type 1.
Cherepanov P; Esté JA; Rando RF; Ojwang JO; Reekmans G; Steinfeld R; David G; De Clercq E; Debyser Z
Mol Pharmacol; 1997 Nov; 52(5):771-80. PubMed ID: 9351967
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of human immunodeficiency virus type 1 isolates by the integrase inhibitor L-731,988, a diketo Acid.
Reinke R; Lee DJ; Robinson WE
Antimicrob Agents Chemother; 2002 Oct; 46(10):3301-3. PubMed ID: 12234866
[TBL] [Abstract][Full Text] [Related]
6. The naphthyridinone GSK364735 is a novel, potent human immunodeficiency virus type 1 integrase inhibitor and antiretroviral.
Garvey EP; Johns BA; Gartland MJ; Foster SA; Miller WH; Ferris RG; Hazen RJ; Underwood MR; Boros EE; Thompson JB; Weatherhead JG; Koble CS; Allen SH; Schaller LT; Sherrill RG; Yoshinaga T; Kobayashi M; Wakasa-Morimoto C; Miki S; Nakahara K; Noshi T; Sato A; Fujiwara T
Antimicrob Agents Chemother; 2008 Mar; 52(3):901-8. PubMed ID: 18160521
[TBL] [Abstract][Full Text] [Related]
7. Development of resistance against diketo derivatives of human immunodeficiency virus type 1 by progressive accumulation of integrase mutations.
Fikkert V; Van Maele B; Vercammen J; Hantson A; Van Remoortel B; Michiels M; Gurnari C; Pannecouque C; De Maeyer M; Engelborghs Y; De Clercq E; Debyser Z; Witvrouw M
J Virol; 2003 Nov; 77(21):11459-70. PubMed ID: 14557631
[TBL] [Abstract][Full Text] [Related]
8. The R263K Dolutegravir Resistance-Associated Substitution Progressively Decreases HIV-1 Integration.
Mesplède T; Leng J; Pham HT; Liang J; Quan Y; Han Y; Wainberg MA
mBio; 2017 Apr; 8(2):. PubMed ID: 28377526
[TBL] [Abstract][Full Text] [Related]
9. Nef expressed from human immunodeficiency virus type 1 extrachromosomal DNA downregulates CD4 on primary CD4+ T lymphocytes: implications for integrase inhibitors.
Gillim-Ross L; Cara A; Klotman ME
J Gen Virol; 2005 Mar; 86(Pt 3):765-771. PubMed ID: 15722538
[TBL] [Abstract][Full Text] [Related]
10. Biochemical screening assays to identify HIV-1 integrase inhibitors.
Clynhens M; Smets A; Vereycken I; Van Loock M; Clayton R; Meersseman G; Goethals O
Methods Mol Biol; 2013; 1030():25-36. PubMed ID: 23821258
[TBL] [Abstract][Full Text] [Related]
11. Human immunodeficiency virus type 1 (HIV-1) integrase: resistance to diketo acid integrase inhibitors impairs HIV-1 replication and integration and confers cross-resistance to L-chicoric acid.
Lee DJ; Robinson WE
J Virol; 2004 Jun; 78(11):5835-47. PubMed ID: 15140981
[TBL] [Abstract][Full Text] [Related]
12. HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase.
Espeseth AS; Felock P; Wolfe A; Witmer M; Grobler J; Anthony N; Egbertson M; Melamed JY; Young S; Hamill T; Cole JL; Hazuda DJ
Proc Natl Acad Sci U S A; 2000 Oct; 97(21):11244-9. PubMed ID: 11016953
[TBL] [Abstract][Full Text] [Related]
13. A Fluorescent Assay to Search for Inhibitors of HIV-1 Integrase Interactions with Human Ku70 Protein, and Its Application for Characterization of Oligonucleotide Inhibitors.
Galkin S; Rozina A; Zalevsky A; Gottikh M; Anisenko A
Biomolecules; 2020 Aug; 10(9):. PubMed ID: 32854330
[TBL] [Abstract][Full Text] [Related]
14. Azido-containing diketo acid derivatives inhibit human immunodeficiency virus type 1 integrase in vivo and influence the frequency of deletions at two-long-terminal-repeat-circle junctions.
Svarovskaia ES; Barr R; Zhang X; Pais GC; Marchand C; Pommier Y; Burke TR; Pathak VK
J Virol; 2004 Apr; 78(7):3210-22. PubMed ID: 15016842
[TBL] [Abstract][Full Text] [Related]
15. Human immunodeficiency virus type-1 integrase containing a glycine to serine mutation at position 140 is attenuated for catalysis and resistant to integrase inhibitors.
King PJ; Lee DJ; Reinke RA; Victoria JG; Beale K; Robinson WE
Virology; 2003 Feb; 306(1):147-61. PubMed ID: 12620807
[TBL] [Abstract][Full Text] [Related]
16. Dicaffeoylquinic and dicaffeoyltartaric acids are selective inhibitors of human immunodeficiency virus type 1 integrase.
McDougall B; King PJ; Wu BW; Hostomsky Z; Reinecke MG; Robinson WE
Antimicrob Agents Chemother; 1998 Jan; 42(1):140-6. PubMed ID: 9449274
[TBL] [Abstract][Full Text] [Related]
17. Structure-activity relationships of HIV-1 integrase inhibitors--enzyme-ligand interactions.
Maurin C; Bailly F; Cotelle P
Curr Med Chem; 2003 Sep; 10(18):1795-810. PubMed ID: 12871105
[TBL] [Abstract][Full Text] [Related]
18. HIV-1 integrase inhibitors: a decade of research and two drugs in clinical trial.
Johnson AA; Marchand C; Pommier Y
Curr Top Med Chem; 2004; 4(10):1059-77. PubMed ID: 15193139
[TBL] [Abstract][Full Text] [Related]
19. HIV type 1 integrase inhibitors: from basic research to clinical implications.
Jegede O; Babu J; Di Santo R; McColl DJ; Weber J; Quiñones-Mateu M
AIDS Rev; 2008; 10(3):172-89. PubMed ID: 18820719
[TBL] [Abstract][Full Text] [Related]
20. Reporter gene expression from LTR-circles as tool to identify HIV-1 integrase inhibitors.
Van Loock M; Hombrouck A; Jacobs T; Winters B; Meersseman G; Van Acker K; Clayton RF; Malcolm BA
J Virol Methods; 2013 Feb; 187(2):238-47. PubMed ID: 23178583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
